DENVER, March 3 /PRNewswire/ -- Pharmatech, Inc., a Research Management Organization (RMO), has contracted with Systems Medicine LLC (SML), a subsidiary of Seattle-based Cell Therapeutics, Inc. (CTI), to provide research and site management services for their phase II open-label clinical study for patients with myxoid liposarcoma with a (12;16) translocation. The study is intended to assess the safety and efficacy of SML's experimental drug product, brostallicin. The trial will also be supported by the Sarcoma Foundation of America (SFA).
Pharmatech will manage this sarcoma trial using its innovative Just-In-Time(TM) (JIT) approach. This streamlined approach was created to increase enrollment in clinical trials for rare cancer disease indications with narrow patient populations. The study sponsor does not open the trial at the site level until a potential patient is identified through basic standard of care procedures, thus saving time, money, and effort for both the sites and the sponsors. Patient enrollment, through Just-In-Time, is further increased because a protocol can be rolled out to a large number of qualified Research Network sites with minimal expense of time and capital.
The SML trial allowed for the formation of a partnership between Pharmatech and the Sarcoma Foundation of America. The union of the two organizations helps create awareness for the Foundation's Sarcoma Patient Registry program. The Registry allows patients to call into the Foundation to sign up for participation in the Registry program. If they consent, then they are notified by the Foundation if a current or future trial fits their specific disease indications. Matthew Alsante, Executive Director, Sarcoma Foundation of America, states, "The collaboration allows for a superior coordination among key players in the clinical trial process. The patients come to the Foundation through our sophisticated Registry. The Foundation takes the incidence data from the Registry to communicate directly with the patients about the clinical trials available to them through partnerships with research management groups such as Pharmatech."
About Pharmatech, Inc.
Pharmatech, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research, while protecting patient safety. Pharmatech provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through organized research networks, the Company focuses on access to clinical trials for patients and clinical investigators. The Network model provides a foundation for the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech, please visit http://www.pharmatech.com.
About Systems Medicine LLC
Systems Medicine, LLC (SML), develops oncology products by integrating predictive cellular pharmacogenomics ("genomics") with world-class clinical and regulatory expertise. This allows SML to develop patient-selective therapies by defining the context of vulnerability of cancer and treating only those patients most likely to respond to specific drugs or drug combinations. For more information on SML and the products that SML has in development, please visit http://www.systems-medicine.com.
About the Sarcoma Foundation of America
The mission of the Sarcoma Foundation is to act as an advocate for increased research to find new and better therapies with which to treat patients with sarcoma. The Foundation has created a Sarcoma Patient Registry program that has the capability to match sarcoma patients into corresponding clinical trials. Please visit their website at http://www.curesarcoma.org for more information on the programs they have in place to help sarcoma patients.
|SOURCE Pharmatech, Inc.|
Copyright©2008 PR Newswire.
All rights reserved